Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Cancer. 2010 Oct 19;117(6):1113–1122. doi: 10.1002/cncr.25527

Figure 6.

Figure 6

Rates of progression-free survival by molecular responses at 1 and 3 months.31

The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia, Vol. 120, No. 6, 2003, 990–999. © 2003 British Journal of Hematology; Reprinted with permission of Wiley-Blackwell, Inc.